531 related articles for article (PubMed ID: 19818352)
1. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
2. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.
Yang H; Zhang Y; Wu M; Li J; Zhou W; Li G; Li X; Xiao B; Christadoss P
Inflamm Res; 2010 Mar; 59(3):197-205. PubMed ID: 19768385
[TBL] [Abstract][Full Text] [Related]
3. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
4. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles.
Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H
Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919
[TBL] [Abstract][Full Text] [Related]
5. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
6. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells.
Aricha R; Feferman T; Scott HS; Souroujon MC; Berrih-Aknin S; Fuchs S
J Autoimmun; 2011 Feb; 36(1):16-24. PubMed ID: 21035305
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis.
Mus AM; Cornelissen F; Asmawidjaja PS; van Hamburg JP; Boon L; Hendriks RW; Lubberts E
Arthritis Rheum; 2010 Apr; 62(4):1043-50. PubMed ID: 20131264
[TBL] [Abstract][Full Text] [Related]
8. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients.
Masuda M; Matsumoto M; Tanaka S; Nakajima K; Yamada N; Ido N; Ohtsuka T; Nishida M; Hirano T; Utsumi H
J Neuroimmunol; 2010 Aug; 225(1-2):123-31. PubMed ID: 20472307
[TBL] [Abstract][Full Text] [Related]
9. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
10. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
[TBL] [Abstract][Full Text] [Related]
11. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
Aricha R; Mizrachi K; Fuchs S; Souroujon MC
J Autoimmun; 2011 Mar; 36(2):135-41. PubMed ID: 21193288
[TBL] [Abstract][Full Text] [Related]
12. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
13. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis.
Nessi V; Nava S; Ruocco C; Toscani C; Mantegazza R; Antozzi C; Baggi F
J Immunol; 2010 Nov; 185(9):5656-67. PubMed ID: 20881192
[TBL] [Abstract][Full Text] [Related]
14. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions.
Hegazy AN; Peine M; Helmstetter C; Panse I; Fröhlich A; Bergthaler A; Flatz L; Pinschewer DD; Radbruch A; Löhning M
Immunity; 2010 Jan; 32(1):116-28. PubMed ID: 20079668
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background.
Shimohata H; Yamada A; Yoh K; Ishizaki K; Morito N; Yamagata K; Takahashi S
J Nephrol; 2009; 22(1):123-9. PubMed ID: 19229827
[TBL] [Abstract][Full Text] [Related]
16. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis.
Qi H; Li J; Allman W; Saini SS; Tüzün E; Wu X; Estes DM; Christadoss P
J Neuroimmunol; 2011 May; 234(1-2):165-7. PubMed ID: 21481948
[TBL] [Abstract][Full Text] [Related]
17. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
18. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17.
Rangachari M; Mauermann N; Marty RR; Dirnhofer S; Kurrer MO; Komnenovic V; Penninger JM; Eriksson U
J Exp Med; 2006 Aug; 203(8):2009-19. PubMed ID: 16880257
[TBL] [Abstract][Full Text] [Related]
19. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
[TBL] [Abstract][Full Text] [Related]
20. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
